Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Capital Expenditures came in at -$8939.0 in Q1 2026, up 38.18% year-on-year from -$6469.2 in Q1 2025, and up 81.2% quarter-over-quarter from -$47544.5 in Q4 2025.
Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026) Analysis & Trends
Oculis Holding AG's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$8939.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 38.18% year-over-year to -$8939.0 in Q1 2026; TTM through Mar 2026 was -$363691.2, a 38.33% decrease from a year earlier, with the FY2025 full-year figure at -$363044.7, down 38.86% from the prior year.
- Capital Expenditures grew to -$8939.0 in Q1 2026 per OCS's latest filing, from -$47544.5 in the prior quarter.
- Across five years, Capital Expenditures topped out at -$5636.8 in Q4 2023 and bottomed at -$1.6 million in Q4 2022.
- The 5-year median for Capital Expenditures is -$65066.7 (2024), against an average of -$251973.4.
- Across the five-year window, Capital Expenditures surged 99.65% in 2023 and plunged 1054.33% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at -$1.6 million in 2022, then jumped by 99.65% to -$5636.8 in 2023, then plunged by 1054.33% to -$65066.7 in 2024, then climbed by 26.93% to -$47544.5 in 2025, then surged by 81.2% to -$8939.0 in 2026.
- Per Business Quant, the three latest OCS Capital Expenditures figures stand at -$8939.0 (Q1 2026), -$47544.5 (Q4 2025), and -$155013.6 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 21.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,939.03 |
| Mar 31, 2026 | -8,939.03 |
| Dec 31, 2025 | -47,544.45 |
| Dec 31, 2025 | -47,544.45 |
| Sep 30, 2025 | -155,013.58 |
| Sep 30, 2025 | -155,013.58 |
| Jun 30, 2025 | -152,194.17 |
| Jun 30, 2025 | -152,194.17 |
| Mar 31, 2025 | -14,459.26 |
| Mar 31, 2025 | -14,459.26 |
| Dec 31, 2024 | -65,066.75 |
| Dec 31, 2024 | -65,066.75 |
| Sep 30, 2024 | -177,747.92 |
| Sep 30, 2024 | -177,747.92 |
| Dec 31, 2023 | -5,636.77 |
| Dec 31, 2023 | -5,636.77 |
| Sep 30, 2023 | -21,510.90 |
| Sep 30, 2023 | -21,510.90 |
| Dec 31, 2022 | -1.62 Mn |
| Dec 31, 2022 | -1.62 Mn |